Title: Pioglitazone: inexpensive; very effective at reducing HbA<sub>1c</sub>; no evidence of bladder cancer risk; plenty of evidence of cardiovascular benefit
Abstract:Diabetic MedicineVolume 36, Issue 9 p. 1185-1186 Letter Pioglitazone: inexpensive; very effective at reducing HbA1c; no evidence of bladder cancer risk; plenty of evidence of cardiovascular benefit Ro...Diabetic MedicineVolume 36, Issue 9 p. 1185-1186 Letter Pioglitazone: inexpensive; very effective at reducing HbA1c; no evidence of bladder cancer risk; plenty of evidence of cardiovascular benefit Robert E. J. Ryder, Robert E. J. Ryder orcid.org/0000-0003-4424-355X City Hospital, Birmingham, UKSearch for more papers by this authorRalph A. DeFronzo, Ralph A. DeFronzo University of Texas Health Science Center, San Antonio, Texas, USASearch for more papers by this author Robert E. J. Ryder, Robert E. J. Ryder orcid.org/0000-0003-4424-355X City Hospital, Birmingham, UKSearch for more papers by this authorRalph A. DeFronzo, Ralph A. DeFronzo University of Texas Health Science Center, San Antonio, Texas, USASearch for more papers by this author First published: 18 June 2019 https://doi.org/10.1111/dme.14053Citations: 4Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat No abstract is available for this article.Citing Literature Volume36, Issue9September 2019Pages 1185-1186 RelatedInformationRead More
Publication Year: 2019
Publication Date: 2019-06-19
Language: en
Type: letter
Indexed In: ['crossref', 'pubmed']
Access and Citation
Cited By Count: 7
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot